Free Trial

Govt Calls on AstraZeneca For Response to Poor Results

SOUTH AFRICA
  • Govt says it has spoken to AstraZeneca about the low efficacy of its vaccine in tackling the SA variant - hoping for a response by the end of the week.
  • Reminder: 70% of SA's vaccine doses were expected to come from AZN, making this a substantial setback and was the primary cause of early ZAR weakness
MNI London Bureau | +44 020-3983-7894 | murray.nichol@marketnews.com
MNI London Bureau | +44 020-3983-7894 | murray.nichol@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.